BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Titan AL, Norton JA, Fisher AT, Foster DS, Harris EJ, Worhunsky DJ, Worth PJ, Dua MM, Visser BC, Poultsides GA, Longaker MT, Jensen RT. Evaluation of Outcomes Following Surgery for Locally Advanced Pancreatic Neuroendocrine Tumors. JAMA Netw Open 2020;3:e2024318. [PMID: 33146734 DOI: 10.1001/jamanetworkopen.2020.24318] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 He R, Yin T, Pan S, Wang M, Zhang H, Qin R. One hundred most cited article related to pancreaticoduodenectomy surgery: A bibliometric analysis. Int J Surg 2022;:106775. [PMID: 35840048 DOI: 10.1016/j.ijsu.2022.106775] [Reference Citation Analysis]
2 Li AY, Visser BC, Dua MM. Surgical Indications and Outcomes of Resection for Pancreatic Neuroendocrine Tumors with Vascular Involvement. Cancers 2022;14:2312. [DOI: 10.3390/cancers14092312] [Reference Citation Analysis]
3 Que QY, Zhang LC, Bao JQ, Ling SB, Xu X. Role of surgical treatments in high-grade or advanced gastroenteropancreatic neuroendocrine neoplasms. World J Gastrointest Surg 2022; 14(5): 397-408 [DOI: 10.4240/wjgs.v14.i5.397] [Reference Citation Analysis]
4 Garnier J, Bonnet J, Palen A, Turrini O. Pancreatoduodenectomy enlarged to the portal vein and hepatic artery with solely venous axis reconstruction. Surg Oncol 2021;40:101703. [PMID: 34992031 DOI: 10.1016/j.suronc.2021.101703] [Reference Citation Analysis]
5 Li K, Yuan J, Li Y, Zhang H, Liu X, Ke N. Successful Neoadjuvant Chemotherapy for Small-Cell Neuroendocrine Carcinoma of the Pancreas: A Case Report. Front Oncol 2021;11:719422. [PMID: 34568048 DOI: 10.3389/fonc.2021.719422] [Reference Citation Analysis]
6 Frey S, Mirallié E, Le Bras M, Regenet N. What Are the Place and Modalities of Surgical Management for Pancreatic Neuroendocrine Neoplasms? A Narrative Review. Cancers (Basel) 2021;13:5954. [PMID: 34885063 DOI: 10.3390/cancers13235954] [Reference Citation Analysis]
7 Merola E, Pascher A, Rinke A, Bartsch DK, Zerbi A, Nappo G, Carnaghi C, Ciola M, McNamara MG, Zandee W, Bertani E, Marcucci S, Modica R, Grützmann R, Fazio N, de Herder W, Valle JW, Gress TM, Fave GD, de Pretis G, Perren A, Wiedenmann B, Pavel ME. Radical Resection in Entero-Pancreatic Neuroendocrine Tumors: Recurrence-Free Survival Rate and Definition of a Risk Score for Recurrence. Ann Surg Oncol 2022. [PMID: 35583694 DOI: 10.1245/s10434-022-11837-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Minczeles NS, van Eijck CHJ, van Gils MJ, van Velthuysen MF, Nieveen van Dijkum EJM, Feelders RA, de Herder WW, Brabander T, Hofland J. Induction therapy with 177Lu-DOTATATE procures long-term survival in locally advanced or oligometastatic pancreatic neuroendocrine neoplasm patients. Eur J Nucl Med Mol Imaging 2022. [PMID: 35230492 DOI: 10.1007/s00259-022-05734-8] [Reference Citation Analysis]